Savara (Nasdaq:SVRA) - Prezzo delle azioni, notizie e analisi

SVRA Panoramica delle azioni

Savara Inc. è un'azienda biofarmaceutica in fase clinica che si occupa di malattie respiratorie rare.

SVRA analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	5/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Si prevede che gli utili cresceranno del 54.21% all'anno

Analisi del rischio

Realizza un fatturato inferiore a 1 milione di dollari ( $0 )

Gli azionisti sono stati diluiti nell'ultimo anno

Savara Inc. Concorrenti

Cogent Biosciences

NasdaqGS:COGT

US$1.1b

Design Therapeutics

NasdaqGS:DSGN

US$336.3m

Allogene Therapeutics

NasdaqGS:ALLO

US$673.3m

Instil Bio

NasdaqCM:TIL

US$161.3m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Savara
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$4.02
Massimo di 52 settimane	US$5.70
Minimo di 52 settimane	US$3.12
Beta	0.95
1Variazione di 1 mese	6.35%
Variazione a 3 mesi	1.01%
Variazione di 1 anno	17.89%
3Variazione a 3 anni	246.55%
Variazione a 5 anni	464.61%
Variazione dall'IPO	-54.11%

Notizie e aggiornamenti recenti

Recent updates

Savara: Trial Successful, But I'm Only Half Convinced

Sep 09

Savara: Today's Data 'Win' Rouses Market All Too Briefly

Jun 26

Savara: The Binary Bet On Phase 3 Data

Jun 07

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

Dec 14

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Feb 16

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Oct 12

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Aug 26

Savara GAAP EPS of -$0.06 in-line

Aug 11

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Jan 24

Is Savara (NASDAQ:SVRA) A Risky Investment?

Jul 05

Savara: They Failed Once, But They Are Trying Again

Jun 07

The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Mar 17

Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Feb 26

Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex

Nov 24

Savara EPS misses by $0.01

Nov 05

Rendimenti per gli azionisti

	SVRA	US Biotechs	US Mercato
7D	10.6%	4.3%	5.1%
1Y	17.9%	29.2%	37.7%

Ritorno vs Industria: SVRA ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 29.2 % nell'ultimo anno.

Rendimento vs Mercato: SVRA ha avuto una performance inferiore al mercato US che ha registrato un rendimento 37.7 % nell'ultimo anno.

Volatilità dei prezzi

Is SVRA's price volatile compared to industry and market?
SVRA volatility
SVRA Average Weekly Movement	6.5%
Biotechs Industry Average Movement	9.5%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	2.9%

Prezzo delle azioni stabile: SVRA non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 7% ) di SVRA è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
n/a	37	Matt Pauls	www.savarapharma.com

Savara Inc. è una società biofarmaceutica in fase clinica che si occupa di malattie respiratorie rare. Il principale prodotto candidato dell'azienda è il molgramostim, un fattore di stimolazione delle colonie di granulociti-macrofagi per via inalatoria, in fase di sviluppo di Fase 3 per il trattamento della proteinosi alveolare polmonare autoimmune. Savara Inc. ha sede a Langhorne, in Pennsylvania.

Savara Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Savara con la sua capitalizzazione di mercato?
SVRA statistiche fondamentali
Capitalizzazione di mercato	US$628.77m
Guadagni(TTM)	-US$75.29m
Ricavi(TTM)	n/a

0.0x

Rapporto P/S

-8.8x

Rapporto P/E

SVRA è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
SVRA Conto economico (TTM)
Ricavi	US$0
Costo del fatturato	US$45.63m
Profitto lordo	-US$45.63m
Altre spese	US$29.66m
Guadagni	-US$75.29m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.46
Margine lordo	0.00%
Margine di profitto netto	0.00%
Rapporto debito/patrimonio netto	26.0%

Come si è comportato SVRA nel lungo periodo?

Vedi performance storica e confronto

SVRA Panoramica delle azioni

Premi

Analisi del rischio

Savara Inc. Concorrenti

NasdaqGS:COGT

US$1.1b

NasdaqGS:DSGN

US$336.3m

NasdaqGS:ALLO

US$673.3m

NasdaqCM:TIL

US$161.3m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Savara Appoints Braden Parker as Chief Commercial Officer

Savara: Trial Successful, But I'm Only Half Convinced

Price target increased by 19% to US$10.71

Savara: Today's Data 'Win' Rouses Market All Too Briefly

Savara Inc. Announces Positive Results from the Pivotal, Phase 3 IMPALA-2 clinical trial

Savara: The Binary Bet On Phase 3 Data

Recent updates

Savara Appoints Braden Parker as Chief Commercial Officer

Savara: Trial Successful, But I'm Only Half Convinced

Price target increased by 19% to US$10.71

Savara: Today's Data 'Win' Rouses Market All Too Briefly

Savara Inc. Announces Positive Results from the Pivotal, Phase 3 IMPALA-2 clinical trial

Savara: The Binary Bet On Phase 3 Data

Savara Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Savara Inc., Annual General Meeting, Jun 06, 2024

Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024

No longer forecast to breakeven

New minor risk - Profitability

Chairman & CEO recently sold US$396k worth of stock

Forecast to breakeven in 2026

Savara Inc. Introduces Apap Clearpath, A Gm-Csf Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

New minor risk - Profitability

No longer forecast to breakeven

Price target increased by 7.3% to US$5.50

Price target increased by 7.5% to US$5.38

New minor risk - Shareholder dilution

New minor risk - Share price stability

Savara Inc. has completed a Follow-on Equity Offering in the amount of $79.994334 million.

Savara Inc. Completes Enrollment of Pivotal Phase 3 Impala-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis

Independent Director recently bought US$259k worth of stock

No longer forecast to breakeven

Price target increased by 21% to US$4.60

Savara Inc. Announces New Leadership Appointments

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Savara Inc. Announces New Leadership Appointments

Independent Director recently bought US$56k worth of stock

Forecast to breakeven in 2025

Independent Director recently bought US$82k worth of stock

Independent Director recently bought US$68k worth of stock

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Independent Director recently bought US$187k worth of stock

Independent Director recently bought US$142k worth of stock

Savara Announces Resignation of Badrul Chowdhury as Chief Medical Officer, Effective on September 9, 2022

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Savara GAAP EPS of -$0.06 in-line

Independent Director recently bought US$138k worth of stock

Savara Inc. has completed a Follow-on Equity Offering in the amount of $60 million.

Savara Inc., Annual General Meeting, Jun 02, 2022

Price target increased to US$4.50

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Independent Director recently bought US$64k worth of stock

Independent Director recently bought US$215k worth of stock

Independent Director recently bought US$176k worth of stock

Independent Director recently bought US$115k worth of stock

Is Savara (NASDAQ:SVRA) A Risky Investment?

Savara Inc. Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial

Savara Inc.(NasdaqGS:SVRA) dropped from Russell 3000E Value Index

Savara: They Failed Once, But They Are Trying Again

Independent Director recently bought US$81k worth of stock

The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Savara Inc. has completed a Follow-on Equity Offering in the amount of $113.011275 million.

Revenue and earnings beat expectations

Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Chairman & CEO recently bought US$50k worth of stock